THE IMPACT OF TREATMENT DURATION ON RELAPSE RATES AND HEALTH CARE COSTS AMONG MEDICAID PATIENTS WITH OPIOID DEPENDENCE TREATED WITH BUPRENORPHINE/NALOXONE
Author(s)
Kharitonova E1, Zah V2, Clay E1, Ruby J3, Aballéa S4, Toumi M4
1Creativ-Ceutical, Paris, France, 2ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro, 3Reckitt Benckiser Pharmaceuticals, Inc./NA, Richmond, VA, USA, 4University Claude Bernard Lyon 1, Lyon, France
OBJECTIVES: Buprenorphine/naloxone (BUP/NAL) combination is a treatment for the opioid dependence. Earlier studies showed that some patients, here, alternated between periods on and off treatment. The aim of this study was to compare health care resource utilization and costs between these patients and patients treated continuously. METHODS: Statistical analyses were conducted on a Medicaid insurance claims database (TruvenHealth MarketScan® Medicaid) from January 2007 to June 2012. Patients with at least two treatment episodes in the first year after the initial filled prescription were identified. The end of a treatment episode was defined as a period of 60 days with no filled BUP/NAL prescriptions following the theoretical end of the last filled prescription. An ordered logistic regression model was used to analyze the impact of initial treatment episode duration on the number of new episodes in the year following the end of the first episode. Healthcare resource utilization and related costs during the first year after initiation were compared between the two groups. RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PMH42
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Mental Health